Orthocell (ASX:OCC) said its revenue came in at AU$3.8 million for the June quarter, up 36% year-over-year from AU$2.8 million in the prior-year quarter, according to a Monday Australian bourse filing.
Cash receipts from customers totalled AU$2.5 million for the quarter, compared to AU$1.6 million in the prior quarter
Its revenue for fiscal year 2026 came in at AU$13.2 million, up 44%.
The firm attributed the rise in revenue to continued adoption of Remplir in Australia and accelerating commercial adoption in the US. Total international revenue from Remplir sales comprises 9% of total quarterly revenue.